We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

MEK Inhibitor U0126

Inhibits Activation of MAPK (ERK 1/2)

  • Used in both in vivo and in vitro studies of MEK
  • Potent: inhibits Raf-activated MEK1/2 in vitro with an IC50 of ~10–20μM
  • Supplied as a dried material

Size

Catalog number selected: V1121

$ 230.00 Your price: Log In

Add to Helix
MEK Inhibitor U0126
5mg
$ 230.00
Your price: Log In

MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2). U0126 inhibits MEK1 with an IC50 of 0.5μM (in vitro). It has been used in both in vivo and in vitro studies of MEK. The chemical identity of MEK Inhibitor U0126 has been confirmed by proton NMR spectroscopy.

Supplied as a dried material. Resuspend 1mg in 234μl of DMSO to produce a stock solution of 10mM.

References

  1. DeSilva, D.R. et al. (1998) J. Immunol. 160, 4175–81.
  2. Favata, M. et al. (1998) J. Biol. Chem. 273, 18623–32.
  3. Goueli, S. et al. (1998) Promega Notes 69, 6–8.
  4. Tolwinski, N.S. et al. (1999) J. Biol. Chem. 274, 6168–74.
  5. Li, C. et al. (1999) J. Biol. Chem. 274, 6747–53.
  6. Duncia, J.V. et al. (1998) Bioorg. Med. Chem. Lett. 8, 2839–44.

Protocols

Specifications

What's in the box?

Item Part # Size

MEK Inhibitor U0126

V112A 5 x 1mg

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Store dried material at –20°C.

Resources

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom